Your browser doesn't support javascript.
loading
The Proteogenomic Landscape of Curable Prostate Cancer.
Sinha, Ankit; Huang, Vincent; Livingstone, Julie; Wang, Jenny; Fox, Natalie S; Kurganovs, Natalie; Ignatchenko, Vladimir; Fritsch, Katharina; Donmez, Nilgun; Heisler, Lawrence E; Shiah, Yu-Jia; Yao, Cindy Q; Alfaro, Javier A; Volik, Stas; Lapuk, Anna; Fraser, Michael; Kron, Ken; Murison, Alex; Lupien, Mathieu; Sahinalp, Cenk; Collins, Colin C; Tetu, Bernard; Masoomian, Mehdi; Berman, David M; van der Kwast, Theodorus; Bristow, Robert G; Kislinger, Thomas; Boutros, Paul C.
Afiliação
  • Sinha A; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
  • Huang V; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Livingstone J; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Wang J; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada; Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L 3N6, Canada.
  • Fox NS; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Kurganovs N; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Ignatchenko V; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Fritsch K; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Donmez N; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
  • Heisler LE; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Shiah YJ; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Yao CQ; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Alfaro JA; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Volik S; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
  • Lapuk A; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
  • Fraser M; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
  • Kron K; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Murison A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Lupien M; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Sahinalp C; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
  • Collins CC; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Tetu B; Department of Pathology and Research Centre of CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.
  • Masoomian M; Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Berman DM; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada; Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L 3N6, Canada.
  • van der Kwast T; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Bristow RG; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada.
  • Kislinger T; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada. Electronic address: thomas.kislinger@utoronto.ca.
  • Boutros PC; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Human Genetics, University of Califor
Cancer Cell ; 35(3): 414-427.e6, 2019 03 18.
Article em En | MEDLINE | ID: mdl-30889379
ABSTRACT
DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic dysregulation on the tumor proteome remains poorly understood. We profiled the genomes, epigenomes, transcriptomes, and proteomes of 76 localized, intermediate-risk prostate cancers. We discovered that the genomic subtypes of prostate cancer converge on five proteomic subtypes, with distinct clinical trajectories. ETS fusions, the most common alteration in prostate tumors, affect different genes and pathways in the proteome and transcriptome. Globally, mRNA abundance changes explain only ∼10% of protein abundance variability. As a result, prognostic biomarkers combining genomic or epigenomic features with proteomic ones significantly outperform biomarkers comprised of a single data type.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Proto-Oncogênicas c-ets / Proteogenômica Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Cancer Cell Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Proto-Oncogênicas c-ets / Proteogenômica Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Cancer Cell Ano de publicação: 2019 Tipo de documento: Article